US 11,918,575 B2
PZA and cytochrome Bc1 inhibitor combination treatment
Koenraad Jozef Lodewijk Marcel Andries, Beerse (BE); Anil Koul, Edegem (BE); and Maria Cristina Villellas Arilla, Turnhout (BE)
Assigned to Janssen Sciences Ireland Unlimited Company, County Cork (IE)
Filed by Janssen Sciences Ireland Unlimited Company, County Cork (IE)
Filed on Dec. 2, 2021, as Appl. No. 17/540,299.
Application 17/540,299 is a division of application No. 16/490,677, granted, now 11,224,596, previously published as PCT/EP2018/054860, filed on Feb. 28, 2018.
Claims priority of application No. 17158607 (EP), filed on Mar. 1, 2017.
Prior Publication US 2022/0088012 A1, Mar. 24, 2022
Int. Cl. A61K 31/4965 (2006.01); A61K 31/438 (2006.01); A61K 31/4545 (2006.01); A61K 31/47 (2006.01); A61K 31/498 (2006.01); A61P 31/06 (2006.01)
CPC A61K 31/4965 (2013.01) [A61K 31/438 (2013.01); A61K 31/4545 (2013.01); A61K 31/47 (2013.01); A61K 31/498 (2013.01); A61P 31/06 (2018.01)] 6 Claims
 
1. A process for preparing a combination product, the process comprising bringing into association the following active ingredients:
(i) Pyrazinamide (PZA), or a pharmaceutically acceptable salt thereof; and
(ii) a cytochrome bc1 inhibitor, or a pharmaceutically acceptable salt thereof.